Meeting
2022 ASCO Genitourinary Cancers Symposium
Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).
Authors
Zachery R Reichert
University of Michigan, Ann Arbor, MI
Zachery R Reichert , Michael Edward Devitt , Joshi J. Alumkal , David C. Smith , Megan Veresh Caram , Philip Palmbos , Ulka N. Vaishampayan , Ajjai Shivaram Alva , Thomas Braun , Sarah Elizabeth Yentz , Phoebe A. Tsao , Robert Dreicer , Frank Cameron Cackowski , Neel Shah , Emma Dean , Simon Smith , Elisabeth I. Heath
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03787680
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 88)
DOI
10.1200/JCO.2022.40.6_suppl.088
Abstract #
88
Poster Bd #
E3
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.
First Author: Zachery R. Reichert
Poster
2020 Genitourinary Cancers Symposium
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.
First Author: Alexandra Sokolova
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
First Author: Elias Chandran